Geopolitics is disrupting medical travel to India
Tensions in West Asia have led patients to postpone non‑urgent medical travel to India, and providers are increasing virtual consultations to adapt—an immediate example of how conflict ripples into global healthcare access. The shift could reshape cross‑border elective care volumes in the near term. (travel.economictimes.indiatimes.com)
Leading corporate hospitals reported overseas patient flows falling between 50% and 75% in the two weeks after the West Asia conflict escalated, with names cited including Fortis, Artemis and Marengo. (economictimes.indiatimes.com) Fortis told analysts the drop in international footfall has already translated to an estimated 15–20% hit to monthly revenues from medical value travel, and said the Middle East accounts for roughly 30% of its international business. (economictimes.indiatimes.com) Hospitals and industry groups singled out airspace closures and flight suspensions as immediate barriers, and recorded passenger airfare increases of roughly 15–25% that are deterring elective travellers. (economictimes.indiatimes.com) Government and immigration figures show India received 644,387 foreign visitors for medical purposes in 2024 and a provisional 450,633 medical arrivals from Jan–Nov 2025, with Bangladesh alone listed as the top source country at 482,336 arrivals in 2024. (indiatoday.in) Several hospital chains have publicly begun redirecting business development toward Southeast Asia, Africa and Central Asia to offset falling Middle East referrals. (economictimes.indiatimes.com) Major providers are routing new and prospective international patients into telemedicine pipelines: Fortis advertises pre‑arrival medical opinions and teleconsultation services for international patients, while India’s national telemedicine service eSanjeevani has logged hundreds of millions of consultations—demonstrating capacity to absorb deferred demand remotely. (fortiscdoc.com) A 2023 FICCI estimate valued India’s medical tourism sector at about $6.5 billion in 2022 and projected it could reach roughly $13 billion by 2026, figures industry executives say are now at risk if cross‑border patient flows remain suppressed. (indiatoday.in)
